Admin-Core

管理核心

基本信息

项目摘要

ABSTRACT The Administrative Core will continue to manage the Center for Translational Therapeutics (CTT) by attending to all fiscal, organizational, programmatic, career-development, communication, mentoring, and evaluation aspects of the Center. The Specific Aims of this Core are: 1) To continue managing all the organizational, fiscal, scientific oversight, communication, reporting and evaluation aspects of the CTT. This will include interacting with other institutional components for the fiscal management of the CTT, the recruitment of new faculty into the Center, and the replacement of target faculty who have attained independence; organizing and supporting External Advisory Committee (EAC) visits; collecting, organizing and re-distributing as appropriate all the information needed for reporting and evaluation of the CTT by the EAC and producing the Annual Progress Report for NIGMS; and maintaining a web presence to connect the CTT with the participating institutions and with other IDeA programs/centers in and outside the state, the NIGMS, and the scientific community. 2) To continue fostering the career development of junior investigators, promote their progress toward independent funding, and support their continued participation in the CTT, once they attain independence. This will include organizing and managing all CTT meetings, seminars, symposia and other similar activities; mediating communication for mentoring activities and for the review of drafts of grant proposals and manuscripts; and ultimately creating a research environment conducive to the development of young scientists and to accelerating discoveries with inherent applicability in the clinical setting. 3) To promote the formation of teams of investigators and continue promoting the generation of new ideas within the CTT and connecting the CTT with surrounding programs. The pilot project program will provide funding for targeted projects each year, aiming at promoting team science, and generating preliminary data leading to applications for multi-investigator and SBIR/STTR grant proposals, alongside the traditional individual R01 or equivalent. In addition to targeted funding for collaborative teams, the CTT will implement specific strategies to promote collaborations, including (but not limited to) targeted hires to complement existing strengths; tailored mentoring and training; structured opportunities for brainstorming and the generation of ideas; and support for the submission of team-based grant proposals. The Administrative Core will be managed by the PI/Center Director, with a half-time Scientific Coordinator and a full-time Program Manager; and by the Steering Committee composed of the PI, Scientific Coordinator and Core Leaders. An Internal Advisory Committee and a cadre of Mentors will assist the PI in the management of the program. In addition, an External Advisory Committee will provide external evaluation, and support the PI in the scientific development of the Center.
抽象的 行政核心将继续通过参加转化治疗中心(CTT)的管理 涉及所有财务、组织、计划、职业发展、沟通、指导和评估 中心的各个方面。该核心的具体目标是: 1) 继续管理所有组织、财政、科学监督、沟通、报告 CTT 的评估和评估方面。这将包括与其他机构组成部分进行互动 CTT 的财务管理、中心新教员的招聘以及目标的更换 已获得独立的教师;组织和支持外部咨询委员会 (EAC) 的访问; 酌情收集、组织和重新分发报告和评估所需的所有信息 由 EAC 负责 CTT 并为 NIGMS 制作年度进度报告;并维护网络 将 CTT 与参与机构以及其他 IDeA 项目/中心联系起来 在国家、NIGMS 和科学界之外。 2)持续培育初级科研人员的职业发展,促进其进步 寻求独立资助,并支持他们在获得 CTT 后继续参与 独立。这将包括组织和管理所有 CTT 会议、研讨会、座谈会和其他会议 类似的活动;调解指导活动和拨款草案审查的沟通 提案和手稿;最终创造一个有利于发展的研究环境 年轻科学家并加速在临床环境中具有内在适用性的发现。 3)推动研究者队伍的组建,不断促进新的研究者的产生 CTT 中的想法以及将 CTT 与周边项目联系起来。试点项目计划将 每年为目标项目提供资金,旨在促进团队科学,并产生 初步数据导致多研究者申请和 SBIR/STTR 拨款提案, 与传统的个人 R01 或同等产品一起使用。除了为合作提供有针对性的资金外 团队,CTT 将实施具体策略来促进合作,包括(但不限于) 有针对性的招聘以补充现有优势;量身定制的指导和培训;结构化机会 集思广益和想法的产生;并支持提交基于团队的拨款提案。这 行政核心将由 PI/中心主任管理,并配有一名半职科学协调员和一名 全职项目经​​理;指导委员会由 PI、科学协调员和 核心领导者。内部咨询委员会和导师骨干团队将协助 PI 管理 程序。此外,外部咨询委员会将提供外部评估,并支持 PI 中心科学发展。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

IGOR B RONINSON其他文献

IGOR B RONINSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('IGOR B RONINSON', 18)}}的其他基金

Synthetic Transcriptional Activators for Cancer Immunotherapy
用于癌症免疫治疗的合成转录激活剂
  • 批准号:
    10850109
  • 财政年份:
    2023
  • 资助金额:
    $ 91.04万
  • 项目类别:
Synthetic Transcriptional Activators for Cancer Immunotherapy
用于癌症免疫治疗的合成转录激活剂
  • 批准号:
    10868915
  • 财政年份:
    2023
  • 资助金额:
    $ 91.04万
  • 项目类别:
Center for Targeted Therapeutics
靶向治疗中心
  • 批准号:
    10372263
  • 财政年份:
    2014
  • 资助金额:
    $ 91.04万
  • 项目类别:
Center for Targeted Therapeutics
靶向治疗中心
  • 批准号:
    9978871
  • 财政年份:
    2014
  • 资助金额:
    $ 91.04万
  • 项目类别:
Center for Targeted Therapeutics
靶向治疗中心
  • 批准号:
    10221696
  • 财政年份:
    2014
  • 资助金额:
    $ 91.04万
  • 项目类别:
Center for Targeted Therapeutics
靶向治疗中心
  • 批准号:
    8885848
  • 财政年份:
    2014
  • 资助金额:
    $ 91.04万
  • 项目类别:
Admin-Core
管理核心
  • 批准号:
    10403529
  • 财政年份:
    2014
  • 资助金额:
    $ 91.04万
  • 项目类别:
Center for Targeted Therapeutics
靶向治疗中心
  • 批准号:
    9794379
  • 财政年份:
    2014
  • 资助金额:
    $ 91.04万
  • 项目类别:
Admin-Core
管理核心
  • 批准号:
    10221715
  • 财政年份:
    2014
  • 资助金额:
    $ 91.04万
  • 项目类别:
METABOLIC ANALYSIS INSTRUMENTATION TO ENHANCE TARGETED THERAPEUTICS STUDIES
代谢分析仪器可增强靶向治疗研究
  • 批准号:
    10400414
  • 财政年份:
    2014
  • 资助金额:
    $ 91.04万
  • 项目类别:

相似海外基金

Access for All in ALS (ALL ALS) West Clinical Coordinating Center
ALS 所有人 (ALL ALS) 西部临床协调中心
  • 批准号:
    10878596
  • 财政年份:
    2023
  • 资助金额:
    $ 91.04万
  • 项目类别:
Colorado Clinical and Translational Sciences Institute (CCTSI)
科罗拉多临床与转化科学研究所 (CCTSI)
  • 批准号:
    10764161
  • 财政年份:
    2023
  • 资助金额:
    $ 91.04万
  • 项目类别:
Impact of Congenital Hyperinsulinism on Trajectories of Neurocognitive Function Across School Age
先天性高胰岛素血症对整个学龄期神经认知功能轨迹的影响
  • 批准号:
    10723317
  • 财政年份:
    2023
  • 资助金额:
    $ 91.04万
  • 项目类别:
Mechanisms of lipid droplet trafficking in hepatocellular carcinoma
肝细胞癌中脂滴运输的机制
  • 批准号:
    10644812
  • 财政年份:
    2023
  • 资助金额:
    $ 91.04万
  • 项目类别:
Genomic Regulation and Translational Potential of a Novel Smooth Muscle Cell-Derived Cell Type in Atherosclerosis
动脉粥样硬化中新型平滑肌细胞衍生细胞类型的基因组调控和转化潜力
  • 批准号:
    10553197
  • 财政年份:
    2022
  • 资助金额:
    $ 91.04万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了